MTA-1 Expression in Glial Tumors and İts Relation with the IDH1/2 Mutation and other Diagnostic and Prognostic Factors

Abstract

Objective: There is limited data on the effect of Metastasis-associated proteins (MTA1) gene expression could predict prognosis or might be a therapeutic target or diagnostic marker in glial tumors. In this study, we aimed to identify MTA1 genetic expression in glial tumors and compare different levels of expression in terms of the types and histopathological, immunohistochemical, and clinical characteristics of the tumors.

Methods: MTA-1 gene expression levels were calculated from the tissue samples of 38 patients operated for glial tumors. The living tissue samples of ten patients operated with the diagnosis of mesial temporal lobe epilepsy were used as the control group. A correlation study was performed using the data on the length of the mass lesion, lobar location, and surrounding edema on preoperative magnetic resonance imaging and histopathological diagnoses, grades (according to WHO 2, 3, 4), Ki67, and isocitrate dehydrogenase enzyme mutation (IDH 1/2) status (+,-) on postoperatively obtained pathological specimens.

Results: In our cases of glial tumors, the mean tissue MTA-1 gene expression value (164.351) was found to be significantly higher than the control group values (1.000), (Z:-4.845, p<0.001). The expression level of tissue MTA-1 in patients with a positive IDH1/2 status (24.098) was significantly higher than that in patients with a negative IDH1/2 (271.360), (Z:-4.743, p<0.001).

Conclusion: Owing to the higher levels of MTA-1 expression in glial tumors and the presence of an inverse correlation with IDH1/2 mutation, it seems that this molecular biomarker has the potential to be a good candidate for diagnostic studies, prediction of prognosis, and possible targeted immunological treatment strategies.